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Objective: A polymorphism of CYP2E1 may be directly associated with the development of
INH hepatotoxicity. We conducted this study to evaluate the association between polymor-
phisms of CYP2E1, Isoniazid (INH) concentration and the acetylator status of INH in cases of
Indonesian tuberculosis patients with drug-induced liver disease (DILI).
Methods: We conducted our study with a cohort design consisting of 55 Indonesian adult
tuberculosis (TB) patients. Acetylating phenotypes were studied in using the metabolic ratio
of plasma AcHZ/HZ. DILI was deﬁned using CTCAV version 4.0. The allelic and genotypic
frequency distributions of CYP2E1 rs 3813867 were studied using the polymerase chain
reaction – ampliﬁcation refractory mutation system (ARMS) methodology.
Results: Patients with an INH concentration of more than 7 mg/mL showed a higher risk of
developing DILI when compared with patients who showed a therapeutic range of 3–6 mg/mL
INH (OR: 1.3, 95% CI: 0.2–8.2). Slow acetylators had a higher incidence of DILI when compared
with rapid acetylators (OR: 4.6, 95% CI: 1.3–15.9). Meanwhile, subjects with GC had a higher
risk of DILI incidence (OR: 4.3, 95% CI: 0.8–24.4).
Conclusion: Our study shows that polymorphisms of CYP2E1 and slow acetylator may have
role in the DILI incidence.
# 2016 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.
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In 2015, the tuberculosis (TB) prevalence in the world reached
42% lower than in 1990. In 2014, of the 9.6 million of TB
incidence, 58% were from South-East Asia and Western-Paciﬁc* Corresponding author. Tel.: +62 274 563515; fax: +62 274 563515.
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0019-5707/# 2016 Tuberculosis Association of India. Published by Elsregion. Still, India, Indonesia and China had the largest
number of cases from global total number (23%, 10% and
10%, respectively). The treatment success rate for newly
diagnosed TB patients reached 86% in 2013 which was still
sustained since 2015.1 Treatment success is the key outcome
of TB burden reduction. Some factors may inﬂuence the).
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education, population covered and centralized or decentra-
lized health care system.2
The TB treatment regimen is a four-drug combination
consisting of isoniazid (INH), rifampicin (R), pyrazinamide (Z),
and ethambutol (E). This anti-tuberculosis therapy can cause
adverse drug events. The most commonly reported adverse
drug event of anti-tuberculosis drugs is hepatotoxicity.3–5
Among these compounds, isoniazid (INH) strongly associated
with anti-tuberculosis drug-induced hepatotoxicity (ATDH) or
drug-induced liver injury (DILI). Previous reports showed INH
induced liver injury or hepatotoxicity in approximately 5% of
patients.4–6 Other studies showed the development of ATDH in
approximately 1 to 36% of patients.7,8 INH is metabolized by N-
acetyltransferase-2 (NAT-2) into acetylisoniazid. Next, the
metabolite is hydrolysed to acetylhydrazine (AcHZ) and hydra-
zine (HZ) by hepatic N-acetyltransferase-2 (NAT-2).9 These
compounds are then oxidized by cytochrome P450 2E1
(CYP2E1) to form intermediate hepatotoxins.10,11
There are large variations in the metabolism of the
antituberculosis drug isoniazid, including polymorphisms of
the NAT-2 gene. This enzyme is markedly decreased in the
livers of slow acetylators (SA). The elimination of INH follows a
bimodal or trimodal distribution consisting of slow (SA),
intermediate (IA) and rapid acetylators (RA). There is a strong
correlation between these phenotypes and NAT2 genotypes in
Caucasians.11–13 Previous studies have reported inconsistent
results on whether slow or rapid acetylators are a risk factor for
INH-induced hepatotoxicity.9,13–15
The objective of this study was to determine the association
between CYP2E1 polymorphisms and the development of DILI
in Indonesians and determine the genotypes and phenotypes
related to a change in the risk of DILI.
2. Materials and methods
2.1. Patients
This study used a cohort design. A total of 55 Indonesian adult
patients with newly diagnosed TB at 20 Public Health Centres
in the Provinces of Yogyakarta (10 Public Health Centres) and
Lampung (10 Public Health Centres) were enrolled. The
patient's recruitment was conducted from January until
December 2013. The inclusion criteria included all adult
patients (age >18 years) newly diagnosed as a pulmonary
TB patient who were receiving category 1 TB medications and
signed the informed consent for study participation. Exclusion
criteria consisted of TB patients with HIV/AIDS, an AST and
ALT two-fold higher than normal baseline concentrations,
hepatitis or a history of hepatitis, a haemoglobin concentra-
tion <8 mg/dL, cessation of medication for more than 2 weeks,
a history of kidney diseases, or refusal of blood sampling
procedures and patients who refused to participate in this
study.
All patients received a standard TB treatment for the ﬁrst
2 months, including oral INH (300 mg), rifampicin (600 mg),
pyrazinamide (20 mg/kg body weight), and ethambutol
(800 mg). After 2 months of treatment, the patients were
given INH and rifampicin for an additional 4 months. The totalPlease cite this article in press as: Perwitasari DA, et al. CYP2E1 polymo
of Indonesian tuberculosis patients, Indian J Tuberc. (2016), http://dx.doi.oduration of antituberculosis treatment was 6 months. Serum
alanine transaminase (ALT), aspartate transaminase (AST)
and alkalyne phosphatase were measured before the anti-
tuberculosis therapy and then monthly until the end of
treatment.
Genomic DNA was extracted from blood samples using a
DNA Gene JET Genomic DNA Puriﬁcation Kit (Thermo
Scientiﬁc®, Nutrilab Pratama, Jakarta, Indonesia) according
to the manufacturer's instructions. Analysis and Identiﬁcation
of SNP (1055) C/G (Rs 3813867) was completed using an
ampliﬁcation refractory mutation system (ARMS) method. Two
primer sets of CYP2E1 (Rs 3813867) were used: forward I ‘‘5-
GTACAAAATTGCAACCTATG-3’’ to detect the CYP2E1 poly-
morphic gene (F-primer – 1), forward II ‘‘5-GTAGAAAATTG-
CAACCTATG-3’’ to conﬁrm the normal gene fragment and (F-
primer – 2) reverse ‘‘5-ATCTTGTCTTTGTTGATCCC-3’’ (Gene-
bank accession number P05181). The cycling conditions
involved preliminary denaturation at 95 8C for 2 min, followed
by 35 cycles of denaturation at 95 8C for 30 s, annealing at 55 8C
for 30 s, and elongation at 72 8C for 30 s, followed by a ﬁnal
elongation step at 72 8C for 2 min. The PCR products of single
nucleotide polymorphism (SNP) (1055) C > G (rs3813867)
were obtained for 55 subjects. The results showed a band at
230 bp. After electrophoresis using a 2% agarose gel, samples
were observed under UV light and imaged. Samples with
homozygote CC (cytosine-cytosine) appeared using primer set
Forward 1-Reverse (F1-R), samples with homozygote GG
(guanine-guanine) appeared using primer set Forward 2-
Reverse (F2-R), and samples with homozygote CG (cytosine-
guanine) appeared using both primer sets F1-R and F2-R.
Venous blood samples were collected 2 h after drug
administration. Determination of acetylator status was made
using the AcHZ/HZ ratio with a cut-off point of 15.00. A slow
acetylator (SA) was deﬁned as an AcHZ/HZ ratio ≤ 15.00, and a
rapid acetylator (RA) was deﬁned as an AcHZ/HZ ratio >15.16
The AST and ALT levels were measured with an automatic
chemical analyser. Isoniazid and its metabolites, HZ and
AcHZ, were measured using HPLC. Statistical signiﬁcance was
analyzed using correlation tests. DILI incidence was deﬁned as
an ALT and/or AST level above the upper limit normal value
(ULN) listed in Common Toxicity Criteria for Adverse Events
version 4.0 (CTCAE v. 4). The normal values of ALT and AST are
0–50 mg/dL and 0–33 mg/dL, respectively, for males. The
normal values for ALT and AST are 0–34 mg/dL and 0–
27 mg/dL, respectively, for females. Increased ALT and/or
AST or an increased ALP were categorized as grade 1+, (>1.0–
2.5  ULN), grade 2+ (>2.5–5.0  ULN), grade 3+ (>5.0–
20  ULN), or grade 4+ (>20.0  ULN).17
This study was approved by the National Ethics Committee
of the National Institute of Health Research and Development,
Ministry of Health, Republic of Indonesia, and written
informed consent was obtained from all participants.
2.2. Statistical methods
Statistical analysis was conducted using the SPSS® statistical
package, version 16.0. The odds ratio (OR) and conﬁdence
interval (CI) were calculated using binary logistic regression
analysis. This analysis evaluated the risk and association of
DILI, INH and acetylator status. Allele frequencies wererphism, acetylator proﬁles and drug-induced liver injury incidence
rg/10.1016/j.ijtb.2016.08.001
Table 1 – Demographics of Indonesian tuberculosis
patients according to genotype.
Genotype
CC CG GG
N (%) N (%) N (%)
Sex
Male 4 (44.5) 15 (53.6) 10 (55.5)
Female 5 (55.5) 13 (46.4) 8 (44.5)
Total 9 (100.0) 28 (100.0) 18 (100.0)
Age (years)
18–35 2 (22.2) 20 (71.4) 10 (55.6)
36–55 5 (55.5) 3 (10.7) 6 (33.3)
>55 3 (33.3) 5 (17.9) 2 (11.1)
Total 9 (100.0) 28 (100.0) 18 (100.0)
Mean  SD Mean  SD Mean  SD P value
ALT (U/L) Baseline
Male 21.8  15.98 23.2  16.81 20.8  11.72 0.07
Female 16.4  6.69 15.3  12.15 14.6  3.99
AST (U/L) Baseline
Male 19.5  9.03 24.4  13.54 23.4  7.19 0.35
Female 24.8  15.89 20.6  9.78 16.2  5.47
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Hardy–Weinberg equilibrium was tested using a chi-square
test (d.f. = 1) for each locus.
3. Results
This study recruited 55 tuberculosis patients. Table 1 shows
the demographics of the patients. There were 9 patients
(16.36%) genotyped as CC (c1/c1), 29 patients (52.73%) geno-
typed as CG (c1/c2) and 17 patients (30.90%) genotyped as GG
(c2/c2). The genotype frequencies were not signiﬁcantly
different from those predicted by the Hardy–Weinberg
equation (P > 0.05). According to sex and age differences, the
CG genotype was predominant over CC and GG. There were
also no signiﬁcant differences between ALT and AST means at
baseline between males and females with different genotypes
(P > 0.05).
Table 2 shows the association between INH concentration,
acetylator status and DILI incidence. Among the 55 tuberculo-
sis patients, there were 25 patients (45%) with DILI. There was
no signiﬁcant difference between INH serum concentrations
and DILI incidence. However, patients with INH serum
concentrations more than 7 mg/mL had a greater tendency
to develop DILI when compared with subjects who had normal
(3–6 mg/mL) and low (3 mg/mL) INH concentrations (OR: 1.3, 95%
CI: 0.2–8.2). There was a signiﬁcant association between
acetylator status and DILI incidence. A total of 17 patients
(30.9%) were identiﬁed as RAs, and the other 38 patients
(69.09%) were SAs. SAs showed a higher risk of developing DILI
when compared with RAs (OR: 4.6, 95% CI: 1.3–15.9).
Table 3 shows the distribution of INH serum concentration
and acetylator status based on genotype. There were 10
patients (16.36%) genotyped as CC (c1/c1), 29 patients (52.73%)
genotyped as CG (c1/c2) and 16 patients (30.90%) genotyped as
GG (c2/c2). There were no signiﬁcant differences in the
frequencies of c1/c1, c1/c2, and c2/c2 genotypes between the
patients with and without DILI. The heterozygous c1/c2
variant showed a higher DILI incidence when compared with
the homozygous c2/c2 variant (OR: 4.3, 95% CI: 0.8–24.4 and OR:
2.5, 95% CI: 0.4–15.5, respectively). We did the stratiﬁed
analysis according to the acetylator data to the INH serumTable 2 – Association between INH concentration, acetylator st
Variable With DILI
N = 25
INH concentration (mg/mL) 0–3 4 
3–6 3 
>7 18 
Acetylators status Rapid acetylators 12 
Slow acetylators 13 
Genotype CYP2E1 CC(c1/c1) 2 
CG(c1/c2) 16 
Genotype CYP2E1 CC(c1/c1) 2 
GG(c2/c2) 7 
OR: odds ratio; CI: conﬁdence interval.
* Signiﬁcant difference (P < 0.05).
Please cite this article in press as: Perwitasari DA, et al. CYP2E1 polymo
of Indonesian tuberculosis patients, Indian J Tuberc. (2016), http://dx.doi.oconcentration as the determinant; however, we did not ﬁnd
signiﬁcant association (P > 0.05, data was not shown). Fur-
thermore, the binary logistic regression analysis was per-
formed; however we also did not ﬁnd signiﬁcant association
(P > 0.05; data was not shown). After performing bivariate
analysis, there was interesting pattern of results in this study,
which are: patients who did not experience DILI had INH
serum concentration between 0 and 7 ng/mL (OR; 1.8; 95% CI:
0.4–8.2). After stratiﬁed by genotyping, we found that the
patients with GG genotype have more possibilities to experi-
ence DILI (OR: 0.7; 95% CI: 0.4–1.1). We conducted the stratiﬁed
analysis according to acetylator status with DILI status as the
determinant of INH serum concentration. We found that
patients without DILI have lower serum concentration INH in
slow acetylator (OR: 1.6; 95% CI: 0.3–7.6).
An INH serum concentration greater than 7 mg/mL was
found to be predominant in allgenotypes. This pattern was
also found for acetylator status. A SA status is dominant in allatus and DILI incidence.
Without DILI
N = 30
Total N OR (CI 95%) P-value
4 8 Reference
4 7 0.6 (0.03–8.9) 0.63
22 40 1.2 (0.2–8.2) 0.83
5 17 Reference
25 38 4.6 (1.3–15.9) 0.02*
7 9 Reference 0.09
13 29 4.3 (0.8–24.4)
7 9 Reference 0.09
10 17 2.4 (0.5–15.5)
rphism, acetylator proﬁles and drug-induced liver injury incidence
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Table 3 – Distribution of INH serum concentration and acetylator status based on genotype.
Variable CYP2E1 genotype
c1/c1 c1/c2 c2/c2 P-value
N = 10 (%) N = 29 (%) N = 16 (%)
INH serum concentration (mg/mL) 0–3 1 (10.0) 4 (13.8) 3 (18.8) 0.70
>3–6 3 (30.0) 2 (6.9) 2 (12.5) 0.53
>7 6 (60.0) 23 (79.9) 11 (68.8) 0.83
Acetylator Status SA 8 (80.0) 19 (65.5) 11 (68.8) 0.65
RA 2 (20.0) 10 (34.5) 5 (31.3) 0.43
i n d i a n j o u r n a l o f t u b e r c u l o s i s x x x ( 2 0 1 6 ) x x x – x x x4
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inﬂuence on DILI risk.
4. Discussion
Our study shows that the CG genotype of CYP2E1 (rs 3813867)
is the most frequent in Indonesian tuberculosis patients.
Moreover, according to the acetylator status, SAs had a
higher incidence of hepatotoxicity when compared with RAs
and SAs with the heterozygous c1/c2 variant (CG). Previous
studies explained a signiﬁcant association between the c1/c1
genotype and the risk of developing DILI by a higher CYP2E1
activity in patients with the c1/c1 genotype and the
inhibitory effect of INH.18,19 Another study showed that
the CYP2E1*1A/*1A polymorphism may confer a greater risk
of INH-induced hepatotoxicity in a heterogeneous ethnic
population; however, the patients in this study were
receiving monotherapy and potential interactions were not
addressed.19 A recent study from Chamoro et al. reported
that the CYP2E1 c1/c2 polymorphism did not show a
signiﬁcance.20 Our study's ﬁndings are in line with previous
studies which reported that acetylator status was a risk
factor for DILI in tuberculosis patients.9,14,15,21
There have been several reports on the relationship
between INH concentration and ATDH. A previous study
showed an association between INH serum concentration and
NAT2 genotype in Chinese tuberculosis patients.22 INH is
hydrolysed by NAT-2 and oxidized by CYP2E1 to form a
hepatotoxic substance.23 However, our study conﬁrmed that
there is no association between these parameters. Our study
reports that around 40% TB patients had higher INH serum
concentrations, and 45% among them are experienced DILI.
Our study is in line with previous data that showed SA status is
signiﬁcantly associated with DILI in the Indonesian popula-
tion.24 Our patients underwent a combination therapy for TB
treatment, including INH, and drug–drug pharmacokinetic and
pharmacodynamic interactions occurred. INH is known to
have a biphasic effect on CYP2E1 activity that consists of
inhibition followed by induction. Many studies have reported
on drug combinations that increase the incidence of antitu-
berculosis drug-induced hepatotoxicity up to 35%.25–28
Huang et al. showed that CYP2E1 by RsaI restriction
polymorphism was associated with susceptibility to INH-
induced hepatotoxicity.20 INH is principally metabolized by
N-acetyltransferase 2 (NAT-2) and cytochrome P450 2E1
(CYP2E1). NAT-2 plays a key role in the detoxiﬁcation and
elimination of drugs, and it is also involved in carcinogenPlease cite this article in press as: Perwitasari DA, et al. CYP2E1 polymo
of Indonesian tuberculosis patients, Indian J Tuberc. (2016), http://dx.doi.ometabolism.29 Modiﬁcations in NAT-2 activity can result in
the accumulation of precursors, such as HZ and AcHZ, leading
to the development of hepatotoxicity.30–32 CYP2E1 is predom-
inantly expressed in the liver where it activates (via oxidation)
low molecular-weight lipophilic compounds, drugs, and
procarcinogens,33 and it is involved in INH metabolism and
generates hepatotoxic intermediates.34,35 The wild-type and
mutated CYP2E1 alleles have been named c1 and c2,
respectively. There are several in vivo studies that have
associated the c1/c1 genotype with increased transcriptional
activity, protein levels, and enzymatic activity.20,21 Therefore,
patients with the CYP2E1 (c1/c1) genotype generate more
hepatotoxins. Other studies have found that the c1/c1
genotype may be a risk factor for INH-induced hepatotoxici-
ty.34,35 These data are in contrast with our present study that
found c1/c2 may be a risk factor for INH-induced hepatotox-
icity in SAs.
This study has some limitations as follows: we did not
consider the complexity mechanism of antituberculosis-
induced hepatotoxicity which was also interfered by roles of
other genes such as NAT2 and GST.36 The other mechanism of
antituberculosis-induced hepatotoxicity which we did not
involve in this study was due to the rifampicin-INH interac-
tion. Rifampicin may induce INH metabolism through CYP2E1
which also induces the hepatotoxicity.37,38 The small sample
size in our study is caused by the one criteria of the study is
newly diagnosed TB patients, which only small number during
the study period.
5. Conclusions
SAs were associated with an increased DILI incidence. A large-
scale population study is needed to conﬁrm the association
between INH serum concentration, CYP2E1 polymorphisms,
acetylator status and DILI.
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